Argus initiated coverage of Novo Nordisk with a Buy rating and $110 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- LLY, ISRG, or JNJ: Which Healthcare Stock Could Generate the Best Returns?
- Craig-Hallum upgrades WW to Hold amid enthusiasm for GLP-1 medications
- Novo Nordisk price target raised to DKK 700 from DKK 685 at Morgan Stanley
- Novo Nordisk, Valo collaborate to develop treatments using human data, AI
- Weight-loss drugs are bad news for medtech makers, Barron’s says